Trial Profile
Safety and efficacy of interleukin-1 inhibitor anakinra for the amelioration of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem cell transplantation after high-dose melphalan.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2022
Price :
$35
*
At a glance
- Drugs Anakinra (Primary)
- Indications Febrile neutropenia; Mucositis
- Focus Adverse reactions
- Acronyms AFFECT-1
- 23 Nov 2020 Status changed from active, no longer recruiting to completed.
- 13 Jun 2019 Planned End Date changed from 1 Nov 2019 to 1 Jun 2020.
- 13 Jun 2019 Status changed from recruiting to active, no longer recruiting.